ProfileGDS5678 / 1417886_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 89% 88% 89% 89% 88% 85% 88% 89% 87% 88% 88% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.906389
GSM967853U87-EV human glioblastoma xenograft - Control 27.0845689
GSM967854U87-EV human glioblastoma xenograft - Control 36.9382588
GSM967855U87-EV human glioblastoma xenograft - Control 47.1271489
GSM967856U87-EV human glioblastoma xenograft - Control 57.0413689
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6813888
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1819385
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7919188
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.9386789
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.7827587
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.860288
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9508288
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0061189
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0970289